Status:
TERMINATED
Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients
Lead Sponsor:
Geriatric Oncology Consortium
Collaborating Sponsors:
Tibotec Pharmaceutical Limited
Conditions:
Non-Hodgkin's Lymphoma
Eligibility:
All Genders
65+ years
Phase:
PHASE2
Brief Summary
Currently there is no one standard of care for older patients with Non-Hodgkin's Lymphoma (NHL). The study will examine the tolerability and feasibility to the combination of Cyclophosphamide, Pegylat...
Detailed Description
Elderly NHL patients tend to tolerate the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) less well when compared to the younger population. Cardiotoxicity, as well as...
Eligibility Criteria
Inclusion
- Age 65 years and older;
- Diagnosis of Non-Hodgkin's lymphoma where therapy with CHOP plus rituximab is considered;
- Previously untreated;
- ECOG 0-2
- Adequate renal and hepatic functions;
- Cardiac ejection fraction at least 50% by MUGA. No significant cardiac abnormalities by EKG;
- Signed informed consent
Exclusion
- CNS involvement by lymphoma;
- Hypersensitivity to study drugs;
- Active infection;
- Prior treatment with monoclonal antibodies for cancer;
- History of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00120198
Start Date
March 1 2005
End Date
September 1 2006
Last Update
November 16 2007
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxnard, California, United States, 93030
2
Washington D.C., District of Columbia, United States, 20007
3
Inverness, Florida, United States, 34452
4
Lecanto, Florida, United States, 34461